发明名称 Salts of the janus kinase inhibitor (R)-3(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
摘要 The present invention provides salt forms of (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile that are useful in the modulation of Janus kinase activity and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
申请公布号 US9376439(B2) 申请公布日期 2016.06.28
申请号 US201414270915 申请日期 2014.05.06
申请人 Incyte Corporation;Incyte Holdings Corporation 发明人 Rodgers James D.;Li Hui-Yin
分类号 A61K31/519;A61P35/00;A61P35/02;A61P35/04;C07D487/04 主分类号 A61K31/519
代理机构 Lathrop & Gage LLP 代理人 Lathrop & Gage LLP ;Trinque Brian C.
主权项 1. A method of treating a cancer selected from the group consisting of breast cancer, Castleman's disease, pancreatic cancer, and leukemia in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound that is (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphoric acid salt, wherein said treating refers to ameliorating or inhibiting the disease in a patient.
地址 Wilmington DE US